242 related articles for article (PubMed ID: 23620771)
21. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
Bushra MU; Rivu SF; Sifat AE; Nahid NA; Ahmed MU; Al-Mamun MMA; Apu MNH; Islam MS; Islam MR; Islam MS; Hasnat A
Mol Biol Rep; 2020 Sep; 47(9):7073-7082. PubMed ID: 32880833
[TBL] [Abstract][Full Text] [Related]
22. VCP gene variation predicts outcome of advanced non-small-cell lung cancer platinum-based chemotherapy.
Peng J; Yang LX; Zhao XY; Gao ZQ; Yang J; Wu WT; Wang HJ; Wang JC; Qian J; Chen HY; Jin L; Bai CX; Han BH; Wang WM; Lu DR
Tumour Biol; 2013 Apr; 34(2):953-61. PubMed ID: 23412975
[TBL] [Abstract][Full Text] [Related]
23. Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer.
Qian J; Qu HQ; Yang L; Yin M; Wang Q; Gu S; Wu Q; Zhao X; Wu W; Wu J; Tan X; Chen W; Wang H; Wang J; Fan W; Chen H; Han B; Lu D; Wei Q; Jin L
Oncologist; 2012; 17(12):1551-61. PubMed ID: 22843554
[TBL] [Abstract][Full Text] [Related]
24. XPG polymorphisms are associated with prognosis of advanced non-small cell lung cancer treated with platinum-based doublet chemotherapy.
Zou HZ; Zhao YQ
Genet Mol Res; 2015 Jan; 14(1):500-6. PubMed ID: 25729984
[TBL] [Abstract][Full Text] [Related]
25. [Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):107-10. PubMed ID: 16750013
[TBL] [Abstract][Full Text] [Related]
26. Gene-gene and gene-environment interactions influence platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Cui JJ; Wang LY; Zhu T; Gong WJ; Zhou HH; Liu ZQ; Yin JY
Sci Rep; 2017 Jul; 7(1):5082. PubMed ID: 28698656
[TBL] [Abstract][Full Text] [Related]
27. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
[TBL] [Abstract][Full Text] [Related]
28. Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer.
Bi N; Yang M; Zhang L; Chen X; Ji W; Ou G; Lin D; Wang L
Clin Cancer Res; 2010 Apr; 16(8):2383-90. PubMed ID: 20332326
[TBL] [Abstract][Full Text] [Related]
29. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
30. Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients.
Cai W; Chen C; Li X; Shi J; Sun Q; Liu D; Sun Y; Hou L; Zhao X; Gu S; Wu Q; Chen H; Zhang W; Jin L; Lu D; Fei K; Su B; Qian J
Future Oncol; 2014 May; 10(7):1175-85. PubMed ID: 24947259
[TBL] [Abstract][Full Text] [Related]
31. ABCC2 polymorphisms and survival in the Princess Margaret cohort study and the NCIC clinical trials group BR.24 trial of platinum-treated advanced stage non-small cell lung cancer patients.
Cuffe S; Azad AK; Qiu X; Qiu X; Brhane Y; Kuang Q; Marsh S; Savas S; Chen Z; Cheng D; Leighl NB; Goss G; Laurie SA; Seymour L; Bradbury PA; Shepherd FA; Tsao MS; Chen BE; Xu W; Liu G
Cancer Epidemiol; 2016 Apr; 41():50-6. PubMed ID: 26816351
[TBL] [Abstract][Full Text] [Related]
32. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Suk R; Gurubhagavatula S; Park S; Zhou W; Su L; Lynch TJ; Wain JC; Neuberg D; Liu G; Christiani DC
Clin Cancer Res; 2005 Feb; 11(4):1534-8. PubMed ID: 15746057
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
34. The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy.
Zheng Y; Deng Z; Yin J; Wang S; Lu D; Wen X; Li X; Xiao D; Hu C; Chen X; Zhang W; Zhou H; Liu Z
Int J Cancer; 2017 Dec; 141(11):2336-2347. PubMed ID: 28791697
[TBL] [Abstract][Full Text] [Related]
35. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
[TBL] [Abstract][Full Text] [Related]
36. XRCC3 Thr241Met is associated with response to platinum-based chemotherapy but not survival in advanced non-small cell lung cancer.
Qiu M; Xu L; Yang X; Ding X; Hu J; Jiang F; Xu L; Yin R
PLoS One; 2013; 8(10):e77005. PubMed ID: 24116196
[TBL] [Abstract][Full Text] [Related]
37. Role of ERCC5 promoter polymorphisms in response to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer.
He C; Duan Z; Li P; Xu Q; Yuan Y
Anticancer Drugs; 2013 Mar; 24(3):300-5. PubMed ID: 23211354
[TBL] [Abstract][Full Text] [Related]
38. Clinical Significance of Long Non-Coding RNA CASC8 rs10505477 Polymorphism in Lung Cancer Susceptibility, Platinum-Based Chemotherapy Response, and Toxicity.
Hu L; Chen SH; Lv QL; Sun B; Qu Q; Qin CZ; Fan L; Guo Y; Cheng L; Zhou HH
Int J Environ Res Public Health; 2016 May; 13(6):. PubMed ID: 27249003
[TBL] [Abstract][Full Text] [Related]
39. Effect of BRCA1 haplotype on survival of non-small-cell lung cancer patients treated with platinum-based chemotherapy.
Kim HT; Lee JE; Shin ES; Yoo YK; Cho JH; Yun MH; Kim YH; Kim SK; Kim HJ; Jang TW; Kwak SM; Kim CS; Ryu JS
J Clin Oncol; 2008 Dec; 26(36):5972-9. PubMed ID: 19018088
[TBL] [Abstract][Full Text] [Related]
40. An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy.
Zhang R; Jia M; Xu Y; Qian D; Wang M; Zhu M; Sun M; Chang J; Wei Q
Int J Cancer; 2018 Mar; 142(6):1218-1229. PubMed ID: 29134637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
